
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Multi-drug-resistant tuberculosis secondary prevention
Introduction
Overview
Overview
Secondary prevention for tuberculosis includes methods for screening and early diagnosis, such as tuberculin skin test (TST) and IGRAs; and to guarantee the correct treatment regimen at the right time to prevent disease progression.
Secondary Prevention
Secondary Prevention
Screening
Tuberculin Skin Test
- Children with close contact with a TB confirmed case should be evaluated for tuberculosis infection.
- TST is the test of choice for screening for tuberculosis infection.
Interferon-Gamma Release Assays (IGRAs)
- IGRA can be used in place of (but not in addition to) TST in screening for M. tuberculosis infection in the following conditions:[1]
- A patient have received BCG vaccination
- Groups that historically have poor rates of return for TST reading.
- TST preferred compared to IGRA for TB screening due to its low cost and high accessibility.[2]
Early Diagnosis
- Early detection of tuberculosis disease is important to give treatment at the appropriate time and prevent complications.
- All patients should be routinely asked about:[3]
- History of TB exposure, infection, or disease
- Symptoms or signs of TB disease
- Medical conditions that increase their risk for TB disease
- Patients with the following characteristics should be tested for tuberculosis:[3]
- Cough for ≥3 weeks
- Loss of appetite
- Unexplained weight loss
- Night sweats
- Hemoptysis
- Hoarseness
- Fever
- Fatigue
- Chest pain
- Patient from an endemic area of TB
Prompt Treatment
- Empiric therapy should be started as soon as a patient has tuberculosis disease confirmed.
- Sputum specimens should be sent for culture and DST before starting treatment.
DOTS-Plus Strategy
- WHO has devised a new strategy to manage MDR-TB using the second line of drugs wihin the DOTS strategy in middle and low income countries. They must be implemented in well functioning national TB programs . The best way to avoid future MDR- TB epidemics is through prevention of development of future drug resistance.
References
References
- ↑ “CDC Interferon-Gamma Release Assays (IGRAs) – Blood Tests for TB Infection”.
- ↑ Hong-Van Tieu, Piyarat Suntarattiwong, Thanyawee Puthanakit, Tawee Chotpitayasunondh, Kulkanya Chokephaibulkit, Sunee Sirivichayakul, Supranee Buranapraditkun, Patcharawee Rungrojrat, Nitiya Chomchey, Simon Tsiouris, Scott Hammer, Vijay Nandi & Jintanat Ananworanich (2014). “Comparing interferon-gamma release assays to tuberculin skin test in thai children with tuberculosis exposure”. PloS one. 9 (8): e105003. doi:10.1371/journal.pone.0105003. PMID 25121513.
- ↑ 3.0 3.1 “CDC Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005”.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
